Related Experiment Videos
Update on Pharmacology for Restenosis
Albert W. Chan1, Derek P. Chew, A. Michael Lincoff
1Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA. lincofa@ccf.org
Current Interventional Cardiology Reports
|April 27, 2001
Summary
Coronary restenosis after stenting is a growing problem. Pharmacologic therapies delivered via stents show promise in preventing this complication by targeting neointimal hyperplasia.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary restenosis is a significant complication of percutaneous coronary intervention, particularly with the widespread use of coronary stents.
- Neointimal hyperplasia is the primary driver of restenosis, necessitating targeted therapeutic strategies.
Purpose of the Study:
- To provide an update on the development of pharmacologic therapies for preventing coronary restenosis.
- To highlight stent-based drug delivery as a promising strategy.
Main Methods:
- Review of current research on antiproliferative agents (e.g., rapamycin, tranilast, trapidil).
- Focus on stent-based pharmacologic therapy for localized drug delivery.
Main Results:
- Antiproliferative agents are in phase III clinical trials for restenosis prevention.
- Stent-based delivery enhances local drug concentrations, offering a promising approach.
Conclusions:
- Pharmacologic therapy, especially when delivered via stents, is a key focus for combating coronary restenosis.
- Continued research and clinical trials are essential to establish the efficacy of these anti-restenosis strategies.